ATEZOLIZUMAB PLUS VEMURAFENIB AND COBIMETINIB PROVIDES FAVORABLE SURVIVAL OUTCOMES IN PATIENTS WITH HIGH TUMOR MUTATION BURDEN AND PROINFLAMMATORY GENE SIGNATURE IN THE PHASE 3 IMSPIRE150 STUDY
No Thumbnail Available
Identifiers
Date
2020-11-01
Authors
Lewis, Karl
Ascierto, Paolo
Robert, Caroline
Munhoz, Rodrigo
Liszkay, Gabriella
De La Cruz Marino, Luis
Olah, Judit
Queirolo, Paola
Mackiewicz, Jacek
Shah, Kalpit
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Bmj publishing group
Metrics
Export
